Under the terms of agreement, EndoCeutics grants Bayer a worldwide, exclusive license to develop, manufacture and commercialize Vaginorm. Further details of the deal have not been disclosed. The transaction is subject to pre-merger notification under the HSR Act.

According to Bayer Schering, a Phase III clinical program for Vaginorm in the treatment of symptoms of vulvovaginal atrophy and female sexual dysfunction in postmenopausal women has been initiated. Many women experience changes in vaginal tissue after menopause.

EndoCeutics is responsible for conducting the Phase III studies for Vaginorm. Thereafter, Bayer is expected to be responsible for the registration and commercialization of Vaginorm.

Phil Smits, head of women’s healthcare at Bayer Schering Pharma, said: “Vaginorm is an important late stage addition to our Gynecological therapy R&D pipeline. We are pleased to work with EndoCeutics towards bringing a new treatment alternative for vaginal atrophy and female sexual dysfunction to an area of high unmet medical need.

“Gynecological therapies are a new growth area adding to our contraception business. Our research, in-licensing and innovation efforts are all geared towards this strategic goal.”

How far this agreement will benefit both the firms?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.